** Shares of specialty pharma firm Scienture Holdings SCNX.O rise ~60% to $3.55 premarket
** SCNX says it is launching Rezenopy nasal spray 10mg, an opioid overdose emergency drug, through a collaboration with Kindeva Drug Delivery L.P.
** Kindeva will manufacture and supply Rezenopy, while SCNX will own the marketing application and be responsible for sales, marketing, and distribution in the U.S.
** Rezenopy is the most potent version of naloxone HCl available in the market, co says
** SCNX gained 81.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.